PVR and non-small cell lung carcinoma: In NSCLC naive to PD-(L)1 inhibitors, ORR was 33% in the PD-L1 tumor proportion score (TPS) ≥1% subgroup and 27% in the PD-L1 TPS < 1% subgroup. Preliminary data suggests the use of PD-L1 as a predictive therapeutic biomarker, however, more data is needed (270).In patients with PD-L1–positive HNSCC, PD-L1 and TMB showed trends of a positive association with response; TIGIT, TcellinfGEP, and PVR did not show an association with response (NCT05007106) (270).